Call to Action: SARS-CoV-2 and CerebrovAscular DisordErs (CASCADE).

Betacoronavirus / pathogenicity COVID-19 Comorbidity Coronavirus Infections / diagnosis Healthcare Disparities / trends Hospital Mortality / trends Hospitalization / trends Host-Pathogen Interactions Humans Incidence Interrupted Time Series Analysis Pandemics Pneumonia, Viral / diagnosis Practice Patterns, Physicians' / trends Prospective Studies Registries Retrospective Studies Risk Factors SARS-CoV-2 Stroke / diagnosis Time Factors Treatment Outcome
COVID-19 Health policy Incidence Mortality National crisis Pandemic SARS-CoV-2 Stroke

Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 21 04 2020
revised: 01 05 2020
accepted: 02 05 2020
entrez: 19 8 2020
pubmed: 19 8 2020
medline: 25 8 2020
Statut: ppublish

Résumé

The novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), now named coronavirus disease 2019 (COVID-19), may change the risk of stroke through an enhanced systemic inflammatory response, hypercoagulable state, and endothelial damage in the cerebrovascular system. Moreover, due to the current pandemic, some countries have prioritized health resources towards COVID-19 management, making it more challenging to appropriately care for other potentially disabling and fatal diseases such as stroke. The aim of this study is to identify and describe changes in stroke epidemiological trends before, during, and after the COVID-19 pandemic. This is an international, multicenter, hospital-based study on stroke incidence and outcomes during the COVID-19 pandemic. We will describe patterns in stroke management, stroke hospitalization rate, and stroke severity, subtype (ischemic/hemorrhagic), and outcomes (including in-hospital mortality) in 2020 during COVID-19 pandemic, comparing them with the corresponding data from 2018 and 2019, and subsequently 2021. We will also use an interrupted time series (ITS) analysis to assess the change in stroke hospitalization rates before, during, and after COVID-19, in each participating center. The proposed study will potentially enable us to better understand the changes in stroke care protocols, differential hospitalization rate, and severity of stroke, as it pertains to the COVID-19 pandemic. Ultimately, this will help guide clinical-based policies surrounding COVID-19 and other similar global pandemics to ensure that management of cerebrovascular comorbidity is appropriately prioritized during the global crisis. It will also guide public health guidelines for at-risk populations to reduce risks of complications from such comorbidities.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
The novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), now named coronavirus disease 2019 (COVID-19), may change the risk of stroke through an enhanced systemic inflammatory response, hypercoagulable state, and endothelial damage in the cerebrovascular system. Moreover, due to the current pandemic, some countries have prioritized health resources towards COVID-19 management, making it more challenging to appropriately care for other potentially disabling and fatal diseases such as stroke. The aim of this study is to identify and describe changes in stroke epidemiological trends before, during, and after the COVID-19 pandemic.
METHODS METHODS
This is an international, multicenter, hospital-based study on stroke incidence and outcomes during the COVID-19 pandemic. We will describe patterns in stroke management, stroke hospitalization rate, and stroke severity, subtype (ischemic/hemorrhagic), and outcomes (including in-hospital mortality) in 2020 during COVID-19 pandemic, comparing them with the corresponding data from 2018 and 2019, and subsequently 2021. We will also use an interrupted time series (ITS) analysis to assess the change in stroke hospitalization rates before, during, and after COVID-19, in each participating center.
CONCLUSION CONCLUSIONS
The proposed study will potentially enable us to better understand the changes in stroke care protocols, differential hospitalization rate, and severity of stroke, as it pertains to the COVID-19 pandemic. Ultimately, this will help guide clinical-based policies surrounding COVID-19 and other similar global pandemics to ensure that management of cerebrovascular comorbidity is appropriately prioritized during the global crisis. It will also guide public health guidelines for at-risk populations to reduce risks of complications from such comorbidities.

Identifiants

DOI: 10.1016/j.jstrokecerebrovasdis.2020.104938 PMID: 32807412 PMC: PMC7205703
pubmed: 32807412
pii: S1052-3057(20)30344-X
doi: 10.1016/j.jstrokecerebrovasdis.2020.104938
pmc: PMC7205703
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

104938

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Postgrad Med J. 2006 Feb;82(964):140-4
pubmed: 16461478
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
J Stroke Cerebrovasc Dis. 2014 Mar;23(3):e229-35
pubmed: 24315721
N Engl J Med. 2008 Jan 31;358(5):475-83
pubmed: 18234752
Immunol Cell Biol. 2019 Jan;97(1):5-16
pubmed: 30022515
Neurology. 2020 May 26;94(21):905-906
pubmed: 32245844
Int J Stroke. 2018 Oct;13(7):687-695
pubmed: 29699457
Brain Behav Immun. 2020 Jul;87:18-22
pubmed: 32240762
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Mayo Clin Proc. 2010 Dec;85(12):1138-41
pubmed: 21123641
Crit Care Med. 2010 Apr;38(4 Suppl):e10-20
pubmed: 20048675
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Int Heart J. 2013;54(5):247-53
pubmed: 24097211
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Database (Oxford). 2018 Jan 1;2018:
pubmed: 29617745
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904

Auteurs

Shahram Abootalebi (S)

Dr. Everett Chalmers Regional Hospital, Dalhousie University, New Brunswick, Canada. Electronic address: dr.shahram.abootalebi@horizonnb.ca.

Benjamin M Aertker (BM)

Department of Neurology, UTHealth McGovern Medical School, The University of Texas at Houston, Houston, Texas, USA. Electronic address: benjamin.m.aertker@uth.tmc.edu.

Mohammad Sobhan Andalibi (MS)

International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: mssha96@gmail.com.

Negar Asdaghi (N)

Department of Neurology, University of Miami, Miami, Florida, USA. Electronic address: nasdaghi@med.miami.edu.

Ozlem Aykac (O)

Department of Neurology and Neurocritical Care, Eskisehir Osmangazi University, Eskişehir, Turkey.

M Reza Azarpazhooh (MR)

Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada; Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: reza.azarpazhooh@lhsc.on.ca.

M Cecilia Bahit (MC)

Chief of Cardiology, INECO Neurociencias, Rosario, Argentina.

Kristian Barlinn (K)

Department of Neurology, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany. Electronic address: Kristian.Barlinn@ukdd.de.

Hamidon Basri (H)

Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia. Electronic address: hamidon@upm.edu.my.

Reza Bavarsad Shahripour (RB)

University of Tennessee, Comprehensive Stroke center, Memphis, Tennessee, USA. Electronic address: rbavarsa@uthsc.edu.

Anna Bersano (A)

Fondazione Istituto Neurologico 'Carlo Besta', Milan, Italy. Electronic address: anna.bersano@istituto-besta.it.

Jose Biller (J)

Department of Neurology, Loyola University Health System, Stritch School of Medicine, Chicago, USA. Electronic address: JBILLER@lumc.edu.

Afshin Borhani-Haghighi (A)

Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Robert D Brown (RD)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: brown@mayo.edu.

Bruce Cv Campbell (BC)

Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia. Electronic address: bruce.campbell@mh.org.au.

Salvador Cruz-Flores (S)

Neurology Department, Texas Tech Health University, El Paso, Texas, USA. Electronic address: salvador.cruz-flores@ttuhsc.edu.

Deidre Anne De Silva (DA)

National Neuroscience Institute, Singapore General Hospital campus, Singapore. Electronic address: deidre.desilva@singhealth.com.sg.

Mario Di Napoli (M)

Department of Neurology and Stroke Unit, San Camillo de' Lellis General District Hospital, Rieti, Italy; Neurological Section, Neuro-epidemiology Unit, SMDN-Centre for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Sulmona, L'Aquila, Italy. Electronic address: mariodinapoli@katamail.com.

Afshin A Divani (AA)

Department of Neurology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.

Randall C Edgell (RC)

Department of Neurology, Souers Stroke Institute, Saint Louis University, USA.

Johanna T Fifi (JT)

Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: Johanna.fifi@mountsinai.org.

Abdoreza Ghoreishi (A)

Department of Neurology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.

Teruyuki Hirano (T)

Department of Stroke and Cerebrovascular Medicine, Kyorin University, Japan. Electronic address: terry@ks.kyorin-u.ac.jp.

Keun-Sik Hong (KS)

Department of Neurology, Inje University, Ilsan Paik Hospital, Goyang, Republic of Korea.

Chung Y Hsu (CY)

Graduate Institute of Clinical Medical Science, China Medical University, Taipei, Taichung. Electronic address: hsuc@mail.cmu.edu.tw.

Josephine F Huang (JF)

Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: huang.josephine@mayo.edu.

Manabu Inoue (M)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. Electronic address: gakinoue@ncvc.go.jp.

Amanda L Jagolino (AL)

Department of Neurology, UTHealth McGovern Medical School, The University of Texas at Houston, Houston, Texas, USA. Electronic address: amanda.l.jagolino@uth.tmc.edu.

Moira Kapral (M)

Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada. Electronic address: Moira.Kapral@uhn.ca.

Hoo Fan Kee (HF)

Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

Zafer Keser (Z)

Department of Neurology, UTHealth McGovern Medical School, The University of Texas at Houston, Houston, Texas, USA. Electronic address: Zafer.Keser@uth.tmc.edu.

Rakesh Khatri (R)

Neurology Department, Texas Tech Health University, El Paso, Texas, USA. Electronic address: rakesh.khatri@ttuhsc.edu.

Masatoshi Koga (M)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. Electronic address: koga@ncvc.go.jp.

Jerzy Krupinski (J)

Department of Neurology, Hospital Universitari MutuaTerrassa, Terrassa (Barcelona), Spain; Department of Life Sciences, CBS, Manchester Metropolitan University, Manchester, UK. Electronic address: jkrupinski@mutuaterrassa.es.

David S Liebeskind (DS)

Department of Neurology, Geffen School of Medicine, UCLA, USA. Electronic address: dliebeskind@mednet.ucla.edu.

Liping Liu (L)

Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.

Henry Ma (H)

Department of Neurology, Monash Health and Department of Medicine, School of Clinical Sciences Monash University, Australia.

Alberto Maud (A)

Neurology Department, Texas Tech Health University, El Paso, Texas, USA.

Louise D McCullough (LD)

Department of Neurology, UTHealth McGovern Medical School, The University of Texas at Houston, Houston, Texas, USA. Electronic address: Louise.D.McCullough@uth.tmc.edu.

Dawn Matherne Meyer (DM)

Department of Neurosciences, UCSD, USA. Electronic address: dmmeyer@health.ucsd.edu.

Victoria Mifsud (V)

Neurologic Institute, Cleveland Clinic Abu Dhabi, UAE. Electronic address: MifsudV@clevelandclinicabudhabi.ae.

Negar Morovatdar (N)

Clinical Research Development Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: MorovatdarN@mums.ac.ir.

Yongchai Nilanont (Y)

Siriraj Stroke Center, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Thomas J Oxley (TJ)

Department of Neurosurgery, Mount Sinai Hospital, New York, USA. Electronic address: tomoxl@mac.com.

Atilla Özcan Özdemir (AÖ)

Department of Neurology and Neurocritical Care, Eskisehir Osmangazi University, Eskişehir, Turkey.

Jeyaraj Pandian (J)

Department of Neurology, Christian Medical College, Ludhiana, India.

Leonardo Pantoni (L)

Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy. Electronic address: leonardo.pantoni@unimi.it.

Nikolaos I H Papamitsakis (NIH)

Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York, USA.

Adrian Parry-Jones (A)

Manchester Centre for Clinical Neurosciences, Salford Royal National Health Service Foundation Trust, Manchester Academic Health Science Centre, Salford, UK. Electronic address: adrian.parry-jones@manchester.ac.uk.

Thanh Phan (T)

Department of Neurology, Monash Health and Department of Medicine, School of Clinical Sciences Monash University, Australia. Electronic address: thanh.phan@monash.edu.

Gustavo Rodriguez (G)

Neurology Department, Texas Tech Health University, El Paso, Texas, USA.

Jose G Romano (JG)

Department of Neurology, University of Miami, Miami, Florida, USA. Electronic address: JRomano@med.miami.edu.

Ziad Sabaa-Ayoun (Z)

Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada; Schulich School of Medicine and Dentistry, Western University, London, Ontario Canada. Electronic address: zsabaaay@uwo.ca.

Hamidreza Saber (H)

David Geffen School of Medicine, Comprehensive Stroke Center, Department of Neurology, University of California, Los Angeles, USA. Electronic address: hsaber@bu.edu.

Payam Sasannezhad (P)

Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sasannejadp@mums.ac.ir.

Jeffrey L Saver (JL)

Department of Neurology, Geffen School of Medicine, UCLA, USA. Electronic address: jsaver@mednet.ucla.edu.

Eugene Scharf (E)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: scharf.eugene@mayo.edu.

Ashfaq Shuaib (A)

Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Electronic address: shuaib@ualberta.ca.

Brian Silver (B)

Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. Electronic address: Brian.Silver@umassmemorial.org.

Shaloo Singhal (S)

Department of Neurology, Monash Health and Department of Medicine, School of Clinical Sciences Monash University, Australia.

Craig J Smith (CJ)

Division of Cardiovascular Sciences, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, UK; Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, UK. Electronic address: craig.smith-2@manchester.ac.uk.

Saverio Stranges (S)

Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg. Electronic address: saverio.stranges@uwo.ca.

P N Sylaja (PN)

Comprehensive Stroke Care Program, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum 695 011, Kerala, India.

Michel Torbey (M)

Department of Neurology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA. Electronic address: mtorbey@salud.unm.edu.

Kazunori Toyoda (K)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. Electronic address: toyoda@ncvc.go.jp.

Georgios Tsivgoulis (G)

Second Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.

Mohammad Wasay (M)

Aga Khan University, Karachi, Pakistan. Electronic address: mohammad.wasay@aku.edu.

Nawaf Yassi (N)

Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. Electronic address: nawaf.yassi@unimelb.edu.au.

Takeshi Yoshimoto (T)

Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. Electronic address: yoshimototakeshi1982@ncvc.go.jp.

Babak Zamani (B)

Neurology department of Iran University of Medical Sciences, Tehran, Iran.

Ramin Zand (R)

Neurology Department, Neuroscience Institute, Geisinger Health System, Danville, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Comorbidité › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Nidovirales › Infections à Coronaviridae › Infections à coronavirus › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Disparités d'accès aux soins › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Mortalité hospitalière › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Soins aux patients › Hospitalisation › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Phénomènes biologiques › Interactions hôte-microbes › Interactions hôte-pathogène › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Analyse de série chronologique interrompue › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Types de pratiques des médecins › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enregistrements › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Angiopathies intracrâniennes › Accident vasculaire cérébral › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Call to Action: SARS-CoV-2 and CerebrovAscular...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Call to Action: SARS-CoV-2 and CerebrovAscular...